SunGen Pharma, a privately held specialty pharmaceutical company, has launched and started commercial shipment of a generic version of Bentyl (Dicyclomine) Injection in the United States, it was reported on Friday.
The product has been launched in collaboration with Camber Pharmaceuticals as SunGen's distribution and marketing partner.
Dicyclomine Hydrochloride Injection USP, 20mg/2mL (10mg/mL) is a sterile injectable in a two ml-vial. It is used to treat patients with severe irritable bowel syndrome and bowel spasms. It had total US sales of USD17m for 2018 according to IQVIA.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval